Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX

Delayed Quote. Delayed  - 02/08 11:27:52 am
0.81 USD   -3.57%
2015 Protalix BioTherapeutics to Conduct Phase III Clinical Trial for ..
2015 PROTALIX BIOTHE : reports 3Q loss
2015 Protalix BioTherapeutics Reports Third Quarter 2015 Financial Res..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
02/02/2016 02/03/2016 02/04/2016 02/05/2016 02/08/2016 Date
0.82(c) 0.7903(c) 0.8(c) 0.84(c) 0.81 Last
47 346 46 060 81 146 75 664 40 886 Volume
-4.65% -3.62% +1.23% +5.00% -3.57% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales 2013 5,32x
Capi. / Sales 2014 2,34x
Capitalization 83,8 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
01/04 PROTALIX BIOTHERAPEUTICS : Shareholder Director Nominations (form 8-K)
2015 PROTALIX BIOTHERAPEUTICS : Studies from Y. Tekoah and Co-Authors Have Provided N..
2015 PROTALIX BIOTHERAPEUTICS : Regulation FD Disclosure, Financial Statements and Ex..
2015 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
2015 Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for ..
2015 PROTALIX BIOTHERAPEUTICS : reports 3Q loss
2015 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition (form 8..
2015 Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results
More news
Sector news : Biotechnology & Medical Research - NEC
11:36a LONZA : Kodiak Sciences Inc. and Lonza Announce Agreements for the Development a..
10:16a UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's
07:31a SANOFI : Appoints muzammil mansuri to executive committee and executive vice pre..
More sector news : Biotechnology & Medical Research - NEC
Comments 
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions